Orange Biomed

Orange Biomed

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://orangebiomed.com

Last Round

Series A

Extension

Dec 10, 2024

Total Funding Raised

$5.07M

Company Overview

Orange Biomed is a healthcare technology company that develops a portable device for measuring glycated hemoglobin (A1c) levels to manage diabetes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Precision Medicine, Patient Engagement

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales

AI Layer

Non-AI

Keywords

portable HbA1c deviceHbA1c testingdiabetes managementmedical devicePOC testingpoint-of-care testingmicrofluidicsrazor and blades modelat-home HbA1c testrapid diagnosticshemoglobin variantsmedical consumablesOTC diagnosticsover-the-counter diagnosticsFDA 510(k)single-cell analysishealth IoTMEMS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orange Biomed Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Orange Biomed Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 10, 2024
Early FundingAug 10, 2022

Orange Biomed Investors

Notable investors and investment history

InvestorRounds
K2 Investment PartnersSeries A Extension
Digital Healthcare PartnersEarly Funding
Seoul New Technology Investment Co.Early Funding
Intops InvestmentEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2025

    Will attend MEDICA 2025 to showcase A1C test.

  • Oct 22, 2025

    Will attend the 2025 Diabetes Technology Meeting to showcase new A1C measurement technology.

Orange Biomed Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Orange Biomed Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Orange Biomed's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range12
Year Founded2021
Last FundingDec 10, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.